Akoya Earnings Reports

Akoya Biosciences reported a decrease in revenue for the third quarter of 2024 compared to the previous year, but improved its gross margin and reduced operating expenses. The company is focused on long-term growth and profitability, and is evaluating strategic alternatives.

Akoya Biosciences reported a 1.5% year-over-year decrease in revenue, totaling $23.2 million for the second quarter of 2024. The company's gross margin increased to 57.8%, and the operating loss decreased to $11.1 million. They are updating the full year 2024 revenue to be in the range of $96-104 million.

Akoya Biosciences reported a revenue of $18.4 million for Q1 2024, a 14% decrease compared to the prior year period. The company faced challenges due to capital expenditure pressures, deferred revenue from pharmaceutical partners, and temporary reagent fulfillment delays. Despite these setbacks, Akoya is committed to achieving operating cash flow breakeven by year end.

Akoya Biosciences reported Q4 2023 revenue of $26.5 million, a 25.0% increase compared to the prior year period. The company's gross margin was 62.7%, and the operating loss decreased by 46.6% to $9.4 million. Cash and cash equivalents totaled $83.1 million.

Akoya Biosciences reported a record revenue of $25.2 million for Q3 2023, a 34% increase compared to the previous year. The company is focused on improving workflow throughput and expanding its menu of ready-to-use panels.

Akoya Biosciences reported a strong financial performance in Q2 2023, achieving record revenue of $23.5 million, a 31% increase year-over-year. The company highlighted its leading position in spatial biology and its focus on moving towards profitability.

Akoya Biosciences reported a strong start to 2023 with record quarterly revenue of $21.4 million, representing a 27% year-over-year growth. The company also achieved a milestone of 1000 spatial instrument placements in April. Akoya is reiterating its full-year 2023 revenue guidance range of $95-98 million.

Akoya Biosciences reported a 31% increase in revenue for Q4 2022, reaching $21.2 million compared to $16.2 million in the prior year period. The company's product revenue increased by 22% to $15.7 million, while services and other revenue grew by 70% to $5.5 million. Gross profit was $12.0 million with a gross profit margin of 57%.

Akoya Biosciences reported a record revenue of $18.9 million for Q3 2022, a 40% increase compared to the previous year. The company also raised its full-year 2022 revenue guidance to $73-75 million.

Akoya Biosciences reported a 37% increase in revenue compared to the prior year period. The company sold 60 instruments, an increase of 94% from the prior year period. They are raising full year 2022 revenue guidance range to $71-74 million.

Akoya Biosciences reported a 38% increase in total revenue for Q1 2022, reaching $16.9 million compared to $12.2 million in the prior year period. The company also raised its full year 2022 revenue guidance to a range of $70-73 million.

Akoya Biosciences reported a strong finish to 2021 with record quarterly revenue of $16.2 million, representing a 26% increase compared to the prior year period. The company's installed base grew to nearly 700 instruments worldwide, and there are approximately 500 publications on Akoya platforms to date. The commercial launch of the PhenoCycler™-Fusion System was a highlight of the quarter.

Akoya Biosciences reported a strong third quarter with total revenue of $13.5 million, a 35% increase year-over-year. The company saw growth in both product and service revenue, and made key additions to its management team and Board of Directors.

Akoya Biosciences reported a strong second quarter, with total revenue reaching $13.1 million, a 53% increase compared to the same period last year. The company saw substantial growth in reagent sales and continued adoption of its CODEX and Phenoptics solutions.

Akoya Biosciences reported total revenue of $12.2 million for the first quarter of 2021, compared to $11.0 million in the first quarter of 2020. Product revenue was $10.0 million, with instrument revenue at $6.8 million and reagent revenue at $2.5 million.